The human immunodeficiency virus (
HIV) protease inhibitor saquinavir shows anticancer activity. Although its
nitric oxide-modified derivative
saquinavir-NO (
saq-NO) was less toxic to normal cells, it exerted stronger inhibition of
B16 melanoma growth in syngeneic C57BL/6 mice than
saquinavir did.
Saq-NO has been shown to block proliferation, upregulate p53 expression, and promote differentiation of C6
glioma and B16 cells. The anticancer activity of substances is frequently hampered by
cancer cell chemoresistance mechanisms. Therefore, we here investigated the roles of p53 and the
ATP-binding cassette (
ABC) transporters P-glycoprotein (P-gp),
multidrug resistance-associated protein 1 (
MRP1), and
breast cancer resistance
protein 1 (BCRP1) in
cancer cell sensitivity to
saq-NO to get more information about the potential of
saq-NO as anticancer
drug.
Saq-NO exerted anticancer effects in lower concentrations than
saquinavir in a panel of human
cancer cell lines. Neither p53 mutation or depletion nor expression of P-gp,
MRP1, or BCRP1 affected anticancer activity of
saq-NO or
saquinavir. Moreover,
saq-NO sensitized P-gp-, MRP1-, or BCRP1-expressing
cancer cells to
chemotherapy.
Saq-NO induced enhanced sensitization of P-gp- or MRP1-expressing
cancer cells to
chemotherapy compared with
saquinavir, whereas both substances similarly sensitized BCRP1-expressing cells. Washout kinetics and
ABC transporter ATPase activities demonstrated that
saq-NO is a substrate of P-gp as well as of
MRP1. These data support the further investigation of
saq-NO as an anticancer
drug, especially in multidrug-resistant
tumors.